Recently, Andrulis et al. reported durable response in a patient harboring BRAF V600E mutation with relapsed MM refractory to all approved therapeutic options after treatment with vemurafenib (Andrulis et al., 2013). This evidence concerns the gene BRAF and Miyoshi myopathy.